A major policy shift is set to accelerate China's cell and gene therapy (CGT) industry. On July 3, 2026, the Comprehensive Department of the National Medical Products Administration released an announcement soliciting public opinion on optimizing the review and approval process for CGT products. This comprehensive policy package introduces streamlining measures across the entire product lifecycle, from clinical development and market approval to post-market process changes and registration testing, delivering a significant regulatory boost to the domestic CGT sector.

The news immediately catalyzed a market rally. On the same day, innovative drug stocks across the A-share and Hong Kong markets surged. The Wind Innovative Drug Index soared over 2% in a single session, with numerous individual stocks jumping more than 10% on increased trading volume. This signals the start of a sector-wide reversal driven by the powerful combination of supportive policy and improving fundamentals.

Understanding the Policy Milestone

This policy represents a critical milestone for China's CGT industry, with its core objective being to comprehensively shorten product development and commercialization timelines through regulatory reform. The policy explicitly supports CGT research and innovation focused on clinical value, targeting key areas such as malignant tumors and rare diseases. It encourages global synchronous development and international multi-center clinical trials, qualifying eligible products for the 30-day fast-track review for innovative drug clinical trials.

For high-value products with novel targets and mechanisms, the policy promises a "one-company-one-policy" approach with early engagement and full-process guidance under a review-and-development linkage principle, including prioritized review for market applications. The review timeline for major post-approval manufacturing process changes has been significantly shortened from 200 to 130 working days. Furthermore, the policy promotes front-loading registration testing, involving quality studies and method validation during early clinical stages to reduce redundant experiments. These end-to-end review accelerations will directly propel the domestic CGT industry from a phase of heavy R&D investment into a period of faster commercial realization.

Broader Sector Momentum

From an industry perspective, this policy is not an isolated benefit but further evidence of the ongoing upgrade within China's innovative drug sector. In the first half of 2026, cross-border licensing deals by domestic biotech firms repeatedly exceeded expectations, and impressive clinical data presentations at top global medical conferences have continued to validate the global competitiveness of local companies.

On the external front, cooling expectations for further U.S. Federal Reserve interest rate hikes have opened a valuation repair window for the rate-sensitive biotech sector. From a capital standpoint, valuations in the healthcare sector remain near historical lows. The second quarter saw a notable surge in corporate buyback announcements from industry players, with 39 new plans initiated, and substantial buybacks by leading firms have been executed, reflecting a steady recovery in industry confidence. With policy, fundamentals, and capital flows aligning, a solid foundation has been laid for a bottom reversal in the innovative drug sector.

Key Companies Poised to Benefit

RemeGen Co., Ltd. stands as a benchmark for Chinese innovative drug globalization, with leading positions in both ADC and cell therapy fields. Its core products continue to exceed commercialization expectations, and its overseas licensing partnerships are making continuous breakthroughs. The optimized CGT review process will directly accelerate the clinical advancement and approval timelines for its cell therapy pipeline. Coupled with ongoing positive clinical data for its core assets, the company offers both earnings certainty and valuation upside, positioning it as a core leader in this market rally.

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a leader in China's chronic disease market, having achieved significant success in its transition towards innovation, with multiple novel products gradually entering harvest phases. Its solid core business provides ample cash flow to support R&D investments. The company's strong surge to a daily limit-up following the policy news signals the market's formal re-rating of the value of its innovative pipeline. As the regulatory environment continues to improve, the approval timelines for its subsequent pipeline products are expected to beat expectations, offering substantial room for valuation recovery.

Dizal Pharmaceutical focuses on developing first-in-class small molecule drugs globally. Its core pipeline boasts best-in-class potential with compelling clinical data, and its overseas commercialization strategy is progressing steadily. The overall optimization of the drug review environment, combined with rising industry interest in CGT, will further accelerate the realization of its R&D pipeline. Alongside a recovery in sector investment and financing, the company's R&D efficiency and commercial value are poised for sustained growth, making it a high-beta play within the innovative drug space.

WuXi AppTec Co., Ltd., as the global leader in full-spectrum CXO services, holds a top-tier position in CGT CDMO and stands to benefit deeply from the recovery in innovative drug R&D spending. The accelerated review policy will stimulate the release of domestic innovative drug R&D demand. Combined with a global recovery in pharmaceutical investment and financing, the company's order visibility continues to improve. Its substantial share buyback program underscores industry confidence. As a core asset in the innovative drug supply chain, it possesses strong earnings growth certainty and long-term investment value.

Zhejiang Tigermed Consulting Co., Ltd. is the dominant domestic clinical CRO, deeply embedded across the entire innovative drug clinical research process. The optimization of CGT reviews will directly drive an expansion in clinical study demand, with the company poised to capture incremental clinical orders first. Alongside steady expansion of its overseas business, it demonstrates robust earnings growth resilience and is a primary upstream beneficiary within the innovative drug industry chain.

CSPC Pharmaceutical Group Limited is a benchmark for innovation transformation among domestic pharmaceutical giants. Its pipeline spans small molecules, biologics, cell therapy, and more, backed by industry-leading commercial capabilities. The consecutive daily limit-up gains of its related listed entities fully reflect market recognition of the value of its innovative pipeline. As the new review policies take effect, the approval processes for several of its pipeline products are expected to accelerate, allowing the long-term value of its innovation transformation to be realized.

Beyond these, other innovative drug players across various sub-sectors, such as Shenlian Bio, Weikang Pharmaceutical, YD Biopharma, and InventisBio, are also positioned to benefit significantly from the improved regulatory environment and recovering sector sentiment, offering considerable rally potential.

The Long-Term Outlook

From a long-term trend perspective, China's pharmaceutical industry is undergoing a transformation from imitation to true innovation. Domestic companies are gradually building global competitiveness. The re-rating of technology platform value, driven by the dual engines of an aging population and globalization, presents a clear long-term thesis. The implementation of these CGT review policies marks not only a crucial milestone for industry advancement but also serves as a core catalyst for the sector's performance. High-quality companies with technological moats and global capabilities are entering a golden period poised for both earnings growth and valuation expansion.